PTO/SB/08a (08-03)

AUG 0 3 2006 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) 1 Sheet of 2

Complete if Known			
Application Number	10/596,479		
Filing Date	June 14, 2006		
First Named Inventor	Bradley L. Urquhart et al.		
Art Unit	N/A		
Examiner Name			
Attorney Docket Number	10935-35		

	U.S. PATENT DOCUMENTS					
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		UŞ-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY			T ⁶
/TPT/		WO 01/30352	05-03-2001	Cary Pharmaceuticals Inc.		
/TPT/		CA 2,265,926	10-08-2000	Khan		

Examiner Signature	/Timothy Thomas/	Date Considered	5/5/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (MPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known			
181		FION DIG	OL OCUPE	Application Number	10/596,479
			CLOSURE	Filing Date	June 14, 2006
51	STATEMENT BY APPLICANT			First Named Inventor	Bradley L. Urquhart et al.
				Art Unit	N/A
(Use as many sheets as necessary)		Examiner Name			
She	eet 2	of	2	Attorney Docket Number	10935-35

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/TPT/	1.	Abstracts: First Canadian Therapeutics Congress, Can. J. Clin. Pharmacol., 2004, pp. e47-e48, e67-e68, Vol. 11, No. 1.	
-	2.	HOUSE, James D. et al., "Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia", Kidney International", 1998, pp.1601-1607, Vol. 54.	
	3.	SMITH, Patrick F. et al., "Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion", J. Clin. Pharmacol., 2003, pp.1324-1328, Vol. 43.	
V	4.	MARE, Suneetha et al., "High performance liquid chromatography analysis of MESNA (2-mercaptoethane sulfonate) in biological samples using fluorescence detection", Biomedical Chromatography, 2005, pp. 80-86, Vol. 19.	

Examiner Signature	/Timothy Thomas/	Date Considered	5/5/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the complete and the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.